Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Trump Says Anthropic No Longer Seen as National Security Threat 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
WALTHAM, Mass., Feb. 02, 2016 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that Company management will present at the 2016 BIO CEO & Investor Conference in New York City on Monday, February 8, 2016 at 5:00 pm ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis and has completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). For more information, please visit www.proteontherapeutics.com.
Investor Contact
George Eldridge, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Press Contact
Chris Erdman, MacDougall Biomedical Communications
781-235-3060
[email protected]
